Sarah Cannon Research Institute at Tennessee Oncology

TriStar Centennial Medical Center

Nashville, TN

Sorting 13 by

Accepting patients

EXCALIBER RRMM

Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Iberdomide, Daratumumab and Dexamethasone VS Daratumumab, Bortezomib, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Learn more
  • CELMoD
  • Randomization
  • Phase 3

Accepting patients

EXCALIBER-Maintenance

Phase 3 Clinical Trial Comparing Iberdomide VS Lenalidomide as Maintenance Therapy Following Autologous Stem Cell Transplant in Participants with Newly Diagnosed Multiple Myeloma
Learn more
  • CELMoD
  • Post-Autologous Stem Cell Transplant
  • Randomization
  • Phase 3

Accepting patients

STOMP

Phase 1B / 2 Study of Selinexor in Combination With Other Treatments for Relapsed/Refractory and Newly Diagnosed Multiple Myeloma.
Learn more
  • CELMoD
  • SINE
  • Phase 1/2

Not currently accepting

KarMMa-2

Phase 2 Clinical Trial Studying the Safety and Efficacy of bb2121 in Participants with Relapsed and Refractory Multiple Myeloma or Clinical High-Risk Multiple Myeloma
Learn more
  • CAR T Cell
  • BCMA
  • High Risk
  • Phase 2
  • Has results

Not yet accepting

BMS-986453

A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
Learn more
  • CAR T Cell
  • BCMA
  • GPRC5D
  • Phase 1

Not yet accepting

DREAMM13

A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function
Learn more
  • Antibody Drug Conjugate (ADC)
  • BCMA
  • Phase 1

Accepting patients

MonumenTAL-1

Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma (MonumenTAL-1)
Learn more
  • Bispecific Antibody
  • GPRC5D
  • Phase 1
  • Has results

Accepting patients

Teclistamab

A Study of Outpatient Administration of Teclistamab, a BCMA-targeting Bispecific Antibody, in Multiple Myeloma Patients
Learn more
  • Bispecific Antibody
  • BCMA
  • Phase 2

Accepting patients

Cemsidomide (CFT7455)

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Learn more
  • IKZF1/3
  • Phase 1/2

Accepting patients

MMSET Inhibitor

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Learn more
  • Phase 1
1 hidden based on your filters. Show All